bpc 157 or BPC-157 Injectable Peptide for Healing & Recovery The Hidden Risks of BPC‑157:

In addition, while a number of the agonists in Table 1 (Families 2-5) have norleucine at Rj, or an amino acid residue, in the practice of various embodiments of this invention a number of an amino acid residues (D or L) may be used at residue Ri, including without limitation, tyrosine, phenylalanine, aspartic acid, arginine, isoleucme, serine, histidine, glycine, cysteine, methionine, tryptophan, norvaline, ornithine, S-benzyl cysteine amino acid residues

Journal of Medicinal Chemistry, 57 (22), 9220

D57 (CTR) and D254 (G), were predicted protonated, however, visual inspection did not support this prediction because of their solvent-exposed location and, therefore, were modelled in the anionic side chain form

CJC-1295, LGD 4033, GW1516, SR9009 these are all unapproved drugs that share similar risks with BPC-157

The axial scans of all control animals showed a significant distance between the threads of the retracted quadriceps muscle and the iliac bone (4.1 0.5 mm), while in all rats treated with BPC 157, there was no distance, indicating the restoration of the musculoskeletal junction ( p 0.05 at least vs